NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
Clinical Trials
3 trialsNCT04074993 2023-09-28
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
National Cancer Center, Korea
Phase 2 Unknown
NCT05361564 2022-05-04
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
Yonsei University
Phase 2 Unknown